Clinical Trials Logo

Uterine Cervical Neoplasms clinical trials

View clinical trials related to Uterine Cervical Neoplasms.

Filter by:

NCT ID: NCT05393440 Recruiting - Clinical trials for Uterine Cervical Neoplasms

First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer

CC-OV01
Start date: September 16, 2022
Phase: Phase 1
Study type: Interventional

This is a two-stage phase I clinical trial with oncolytic viruses BS-006 in recurrent or metastasis cervical cancer patients who failed in second line treatment.

NCT ID: NCT05390567 Not yet recruiting - Clinical trials for Cervical Cancer Screening Methods

Project CONTINUITY: Promoting Evidence-Based Cancer Screening Among Underserved Women

Start date: June 1, 2024
Phase:
Study type: Observational

Project CONTINUITY (Connecting You to Care in the Community) was developed to increase adherence to cervical cancer screening regimens from initial screening to needed follow-up care by (1) providing personalized approaches to improve adherence through the combined use of patient choice for the initial screening method (Pap/HPV co-testing vs. HPV self-test collection), community clinical navigators and community health workers (CHWs), customized messages and support for patient portal access for test results and (2) implementing strategies to address social determinants of health (SDoH) that may influence an individual's ability to adhere to the screening regimen, with an initial focus on removing transportation barriers through the use of a mobile outreach clinics (MOC).

NCT ID: NCT05388162 Completed - Cervical Cancer Clinical Trials

A Non-inferiority Evaluation of a Smart-phone Based Cervical Imaging Device.

Start date: November 2014
Phase: N/A
Study type: Interventional

When a woman has an abnormal pap smear or tests positive for a high risk strain of the HPV virus, the current standard of care includes culposcopic examination of the cervix with biopsy. A culposcope is essentially a microscope for examining the cervix. Culposcopes cost $5-10,000 each. The device being tested in this trial is an adaptor for a smart phone that will cost ~ $125. The larger goal of this line of studies see if the images obtained using the smart phone adaptor are non-inferior to those obtained with standard culposcopes. If the device is found to provide images equal to those of standard culposscopes, it could save thousands of dollars in healthcare expenditure currently that go to the purchase and maintenance of culposcopes. This has potential world-wide applications, especially for resource poor countries. This initial trial is a non-inferiority trial to compare the images obtained with the smart phone based device of those obtained by a standard culposcope

NCT ID: NCT05385406 Recruiting - Cervical Cancer Clinical Trials

HPV Screening With Triage by HPV Genotyping Versus Visual Inspection With Acetic Acid

Start date: December 6, 2022
Phase: N/A
Study type: Interventional

Cervical cancer is the leading cause of cancer death among women in sub-Saharan Africa, despite the existence of effective prevention and screening methods. Because vaccination rates against human papillomavirus (causing nearly all cervical cancers) are still insufficient in some low-resource countries, early detection and treatment of cervical lesions at risk of progressing to cancer are crucial components of cervical cancer control. Therefore, it is essential to find the most reliable and appropriate screening strategy in the context of low-resource countries in order to identify women in need of treatment and thus prevent the development of cervical cancer. The objective of our study is to compare two different methods of cervical cancer screening adapted to low-resource settings, in two study centers in Cameroon.

NCT ID: NCT05385172 Completed - Clinical trials for Being a Woman Aged 18-65

Evaluation of the Effectiveness of the Video Prepared to Raise Cervical Cancer Awareness in Women Between the Ages of 18 and 65 Via Social Media.

Start date: February 1, 2020
Phase:
Study type: Observational

This research, a quasi-experimental study based on the comparison of the pre-test and post-test results of individuals in a single group is conducted to raise awareness about cervical cancer in women aged 18-65 years. The questionnaire includes 32 questions about the individual's socio-demographic characteristics, pregnancy, and sexual life information, cervical cancer, pap-smear test, and HPV vaccine information, as well as a 27-item 3-point likert type to measure cervical cancer risk factors, symptoms, and prevention. A survey form consisting of 61 questions, consisting of 2 questions and 2 guestions for evaluating the animated training video, and an informative animated training video of 4 minutes and 33 seconds constituted the data collection tools. During the Covid-19 pandemic, the study has completed with 433 people who participated voluntarily by directing the participants via online platforms (WhatsApp / Instagram / E-mail) using the snowball sampling method of survey applications. The women who participated in the research completed the first part by watching the informative animated training video at the end of the questionnaire form.

NCT ID: NCT05384366 Completed - Cervical Cancer Clinical Trials

Neoadjuvant Chemotherapy in Cervical Cancer

Start date: August 1, 2020
Phase: Phase 3
Study type: Interventional

Cervical cancer represents the second commonest cancer in women worldwide, with 500,000 new cases and 300,000 deaths reported yearly. Among cervical cancer cases, 80% occur in developing countries and about 70% are identified as advanced cancer. According to the International Federation of Gynecology and Obstetrics (FIGO) staging system, a locally advanced cervical cancer includes stage IB2 to IIB. Treatment modalities include radical surgery with or without adjuvant radiotherapy (RT), Neoadjuvant Chemotherapy (NAC) plus radical hysterectomy with or without adjuvant RT, and concomitant chemo radiation. Currently, platinum based concurrent chemoradiotherapy is the gold standard for locally advanced cervical carcinoma. Neoadjuvant chemotherapy has many advantages: decreasing tumor size making surgery easier with improved rate of complete resection, decreased pelvic recurrence rate significantly, decreasing rate of parametrial invasion and lymph node metastasis, better brachytherapy distribution, minimal radiation toxicity, and 15% absolute increase of 5-year survival. This study will evaluate various factors i.e. patient related (Age, Menopausal status, HPV, HIV, Comorbidities), Tumor related pathological stages (TNM), grade, lymphovascular perineural invasion, lymph nodes, extranodal extension, tumor margins including radial margin, type of tumor i.e. Adeno vs squamous, mutation profile and Treatment related factors (type of NAC, duration of NAC, no of cycles of NAC).

NCT ID: NCT05378542 Recruiting - Cancer Clinical Trials

Mobile Health Application Developed for Cervical Cancer

Start date: April 22, 2022
Phase: N/A
Study type: Interventional

The main purpose of this research is to evaluate the effect of the nursing care that participants receive with the mobile health application for cervical cancer on raising awareness about cervical cancer. The study conducted through the mobile health application developed to raise awareness about cervical cancer; It is thought that it is important in terms of raising awareness of participants, easing the work-time burden of health personnel in this period, and reducing the cost of health care through early diagnosis and treatment, and will set an example for future studies. Positive outputs from the mobile application will allow the application to be used on national and international platforms.

NCT ID: NCT05378087 Recruiting - Clinical trials for Locally Advanced Cervical Cancer

Comparing the Efficacy of Surgery Staging and Image Staging of Locally Advanced Cervical Cancer

Start date: June 27, 2022
Phase: N/A
Study type: Interventional

The study is a domestic multicenter, prospective, non-randomized controlled concurrent trial. It will be assessed whether surgery staging on locally advanced cervical cancer is superior to image staging for improving progression-free survival and overall survival.

NCT ID: NCT05372484 Recruiting - Cervical Cancer Clinical Trials

PEER Trial: Part 2 Rice Technologies

Start date: March 24, 2021
Phase: N/A
Study type: Interventional

The study aims to compare the accuracy of the lateral flow test to detect HPV at the POC with commercially available HPV test and to determine the diagnostic accuracy and reliability of a multimodal optical imaging system to detect cervical dysplasia, with the gold reference standard of histopathology.

NCT ID: NCT05371353 Recruiting - Vaginal Cancer Clinical Trials

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

Start date: May 14, 2022
Phase:
Study type: Observational

To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.